Publications

Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial

 5
Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer’s disease: a phase 1b, randomized, double-blind trial

Tags:

Previous Article

Targeting of stromal states in pancreatic cancer

Next Article

Immune therapy for Alzheimer's?

Related Posts

Proteogenomic analysis reveals adaptive strategies for alleviating the consequences of aneuploidy in cancer

Proteogenomic analysis reveals adaptive strategies for ...

 104

Microbial metabolism of food allergens determines the severity of IgE-mediated anaphylaxis

Microbial metabolism of food allergens determines the s...

 42

Elevated mitochondrial membrane potential is a therapeutic vulnerability in Dnmt3a-mutant clonal hematopoiesis

Elevated mitochondrial membrane potential is a therapeu...

 94